Search - tctmd.com

Displaying 321 - 340 of 534

Sort: Relevancy | Date

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

News Daily News

Study Questions Role of BP Meds in Patients With Hypertension but No Other CVD Risk Factors

L.A. McKeown

October 30, 2018

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Shelley Wood

October 22, 2018

News Daily News

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Michael O'Riordan

October 15, 2018

News Conference News TCT 2018

Statin Preloading Benefit More Pronounced in STEMI Patients: SECURE-PCI

Michael O'Riordan

October 05, 2018

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

Caitlin E. Cox

September 04, 2018

News Conference News ESC 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Michael O'Riordan

August 27, 2018

News Conference News ESC 2018

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

Shelley Wood

August 25, 2018

News Daily News

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

Michael O'Riordan

August 13, 2018

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Todd Neale

July 02, 2018

Podcast Heart Sounds

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

L.A. McKeown

May 15, 2018

News Conference News EAS 2018

Can Clinicians Really Put a Stop to Atherosclerosis? Experts Explore the How and When of CVD Prevention

Yael L. Maxwell

May 07, 2018

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

News Daily News

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Michael O'Riordan

April 25, 2018

News Daily News

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Michael O'Riordan

April 24, 2018

Advertisement

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Study Questions Role of BP Meds in Patients With Hypertension but No Other CVD Risk Factors

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Statin Preloading Benefit More Pronounced in STEMI Patients: SECURE-PCI

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

TCTMD’s Top 10 Most Popular Stories for August 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Top Stories in Cardiology: May 2018

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

Can Clinicians Really Put a Stop to Atherosclerosis? Experts Explore the How and When of CVD Prevention

Alirocumab Price Slashed in Deal With Express Scripts

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content